贵州百灵：糖宁通络片获临床试验批准

Core Viewpoint - Guizhou Bailing's subsidiary, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its drug, Tangning Tongluo Pian, aimed at treating type 2 diabetes [1] Group 1: Company Developments - The clinical trial application for Tangning Tongluo Pian, a Class 1 new traditional Chinese medicine developed over ten years, has been approved for use in type 2 diabetes [1] - The drug previously received clinical trial approval in 2024 for non-proliferative diabetic retinopathy [1] - The current clinical trial will explore the drug's efficacy for type 2 diabetes with damp-heat syndrome, indicating an expansion of its therapeutic indications [1] Group 2: Product Efficacy - Tangning Tongluo Pian is designed as a pure traditional Chinese medicine to treat both treated and untreated type 2 diabetes patients [1] - The drug aims to adjust the body's endocrine functions, improve disease symptoms, and reverse biochemical indicators, demonstrating promising efficacy [1]